Pharmacology/Conditioning Regimens Flashcards
Abatacept
biological agent, interferes with T-cell activation
Eculizumab
immunosuppressive drug, can treat TMA
Rituximab
Targets CD20+ B cell malignancies; due to infusion reactions (common s/e), use premeds then start at slow rate and titrate up; also screen for HBV
Autologous Car T cell therapy
Genetically modifying T-cells to fight cancerous cells; alter genes inside T-cells by adding chimeric antigen receptor (CAR) that will help T-cells attach to specific cancer cell antigen (ex: CD19 antigen in certain lymphomas and leukemias)
KYMRIAH
CAR-T cell medication used to treat B-cell leukemia, using bodies own T-cells, modifying them, and then re-implanting them to fight cancerous cells
Tacrolimus
Immunosuppressive drug/calcineurin inhibitor that works against helper T-cells, preventing production of IL-2
Campath
Also known as alemtuzumab - commonly causes hypersensitivity reaction
May cause rigors - so have Demerol on hand
Ursodiol
VOD ppx
Cyclophosphamide common s/e
- n/v
- Hemorrhagic cystitis due to acrolein as byproduct of cytoxan
- SIADH - b/c Cytoxan can be toxic to renal collecting tubulues and anti-diuretic hormone activity
Cytoxan management (2, think ppx)
- MESNA
- Hyper hydration (using fluid containing at least 0.45% NaCl. Achieve urine specific gravity ≤ 1.010 prior to start of cyclophosphamide)
Cyclophosphamide adverse effects (4)
- n/v
- Hemorrhagic cystitis due to acrolein as byproduct of cytoxan
- SIADH - b/c Cytoxan can be toxic to renal collecting tubulues and anti-diuretic hormone activity
- cardiotoxicity
Busulfan and pharmacokinetics
type of chemotherapy; pharmacokinetics are very important, always get busulfan levels to monitor for steady stead
If too high - risk of VOD
If too low - won’t kill cancer cells // or risk for engraftment failure
Carboplatin, cisplatin (platins) monitoring (3)
- Ototoxic, need baseline audiogram
- Highly emetogenic, but can be delayed n/v
- Kidneys - very nephrotoxic
Etoposide monitoring (2)
- hypersensitivy rxns b/c it contains preservative
2. hypotension - monitor BPs (if hypotensive, stop infusion, give bolus, then restart at 1/2 rate)
Targeted AUC range for non-myeloablative busulfan dosing
600-750
Busulfan infusion
Always starts with saline, not Bu, and ends with NS flush so that drug level reflects entire dose infused
*Stop clock should be involved for Bu kinetcs
Common toxicities of Busulfan (7)
- N/v - give IVF and anti-emetics
- Mucositis
- Seizures (ppx with anticonvulsant, usually Ativan)
- Myelosuppressive (decreased BMT activity - fewer WBC, RBC and platelets)
- Skin changes: bronzing and darkening of skin - temporary
- Hepatotoxicity
- Intersitial Pneumonia